Latest Information Update: 19 Feb 2016
At a glance
- Originator Fuji Yakuhin
- Mechanism of Action Cyclooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Overactive bladder
Most Recent Events
- 19 Feb 2016 Clinical trials in Overactive bladder in Japan (Parenteral)
- 01 Feb 2010 Preclinical trials in Overactive bladder in Japan (Parenteral)